Information Center
Xinkanghe XKH002 has received approval for the Investigational New Drug (IND) application from the FDA in the United States.
Release time:
2023-02-10 13:25
In Beijing, China, on February 10, 2023, XinKangHe Bio, a company focused on the research and development of innovative immunotherapy drugs, announced that its independently developed innovative drug B7S1 blocking antibody XKH002 has received clinical trial application (IND) approval from the US FDA for the treatment of tumors. The product has also completed the Pre-IND communication process in China. As a "first-in-class" B7S1 blocking antibody, XKH002 has great development potential, especially for patients who do not respond to PD-1/PD-L1 antibody therapies, have poor responses, or have developed resistance. XinKangHe will rapidly advance the clinical development of this product.
About XKH002
XKH002 is a recombinant anti-B7S1 blocking humanized IgG4 monoclonal antibody independently developed by XinKangHe Bio. XKH002 can specifically bind to B7S1 and effectively block the inhibitory effect of B7S1 on T cell proliferation and immune response. XKH002 helps restore and enhance the body's antitumor immune response and has broad-spectrum anti-cancer potential..
About XinKangHe Bio
XinKangHe Bio was established in 2015, founded by Academician Dong Chen, who is the director of the Shanghai Institute of Immunotherapy Innovation, assistant president of Shanghai Jiao Tong University, professor at the School of Medicine, and professor at Tsinghua University School of Medicine, an internationally renowned immunologist. The company is committed to developing innovative drugs with independent intellectual property rights, based on cutting-edge international immunology research, focusing on the development of macromolecular drugs in the fields of autoimmune diseases and immuno-oncology, aiming to provide globally innovative or best-in-class treatment solutions for patients. The company adheres to the research and development philosophy of "innovation, precision, quality, and focus," combining solid basic science with translational medicine, and has multiple globally independent intellectual property innovative pipeline products and new indications entering clinical stages. XinKangHe will continue to delve into areas of unmet clinical needs in inflammation/autimmune diseases and tumor immunotherapy, and looks forward to deep cooperation with innovative pharmaceutical companies at home and abroad.
xkh002, innovation, b7s1, IND
Related News
Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com